Silicon Valley Bank Releases First Innovation in Women’s Health Report

SAN FRANCISCO, Jan. 8, 2024 — Despite ongoing economic headwinds and a pressured venture fundraising environment, investment in startup companies addressing women’s health is on the rise. According to a recent report from Silicon Valley Bank (SVB), a division of First Citizens Bank, investment in women’s health companies increased 314% since 2018, while overall investment for the health sector increased 28%.

SVB’s Innovation in Women’s Health Report examines fundraising and investment activity as well as capital and valuation trends across the sector. The report defines women’s health as healthtech, biopharma, diagnostics/tools, and medical device companies that address underserved care needs for women. This includes conditions that uniquely impact women, conditions that differently or disproportionately impact women, and conditions that are marked by gender-based discrepancies in care.

“Despite broader challenges in the larger venture capital landscape, women’s health is showing significant momentum and progress,” said Raysa Bousleiman, co-author of the SVB Innovation in Women’s Health report and VP of Venture Capital Relationship Management for Life Science and Healthcare at SVB. “Investors and companies are challenging the misconception that women’s health is restricted to reproductive years and realizing the tremendous opportunity to address the complete spectrum of health needs throughout a woman’s life. Investments are increasingly shifting into emerging areas such as menopause, pelvic health and mental health.”

Along with other startups, women’s health companies saw valuations drop in 2023. Women’s health companies are typically valued lower than healthcare companies overall, with seed stage women’s health companies consistently valued 20% lower than overall healthcare companies at the seed stage, according to the data. One reason for the lower valuations could be lack of data collection on women’s health conditions, SVB reported.

“The lack of data on women’s health can be a roadblock for founders when convincing investors there is a need for their company, for accurately estimating market size and for receiving FDA approval,” said Bousleiman. “However, valuations could increase as investors are encouraged by efforts such as the White House Initiative on Women’s Health Research, which aims to close the research gaps in the sector. As clinical trials move forward and more data becomes available, the clinical development of diagnostics, devices and therapeutics to address women’s health issues will progress.”

Key Report Findings: Innovation and Investment in Women’s Health

• With a 314% increase in women’s health venture capital investment since 2018, 2023 will rank as a top funding year for the sector
• Investments in non-reproduction startups reached $435 million in Q3 2023, indicating a shift in the long-held misconception that fertility and pregnancy are the sole focus of women’s health
• Averaging $182M investment per quarter, biopharma surpassed healthtech as the top funded women’s health subsector in 2023
• 76% of women’s health companies have a female founder which is three times higher than companies across the overall innovation ecosystem

Delivering relevant insights on the current and future state of the Healthcare market, SVB will next release its 2024 Healthcare Exits and Investments report on January 17^th, 2024. This annual report analyzes trends for venture capital investing, fundraising, M&A activity and IPOs for biopharma, medical device, diagnostics and tools, and healthtech sectors in the US and Europe. Early data indicates US investors raised $19B for new health-focused VC and growth funds in 2023, the third highest amount for any year.

Bousleiman, and other leaders from SVB’s Life Science and Healthcare practice, will preview the 2024 Healthcare Exits and Investments report during the J.P. Morgan Healthcare conference this week in San Francisco. On Wednesday, the team will also be speaking at select industry events surrounding the conference including:

To access the complete “Innovation in Women’s Health report” and to watch SVB’s recent webinar featuring investor, founder and researcher perspectives, “Unlocking the Blue Ocean Opportunities in Women’s Health,” please visit Innovation in Women’s Health | Silicon Valley Bank (svb.com)

About Silicon Valley Bank

Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world’s most innovative companies and investors. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital and premium wine industries. SVB operates in centers of innovation throughout the United States, serving the unique needs of its dynamic clients with deep sector expertise, insights and connections. SVB’s parent company, First Citizens BancShares, Inc. (NASDAQ: FCNCA), is a top 20 U.S. financial institution with more than $200 billion in assets. First Citizens Bank, Member FDIC. Learn more at svb.com

SOURCE Silicon Valley Bank

TOKYO and MENLO PARK, Calif., Jan. 8, 2024 — Taiho Pharmaceutical Co., Ltd. and Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, announced today that Taiho Ventures has increased its investment pool by $100 million from $300 million to $400 million.

Since its inception in 2016, Taiho Ventures has been actively searching for opportunities to invest in promising start-up companies around the world that conduct innovative first-in-class drug discovery and establish unique platform technologies, primarily in the oncology field. The investment firm has built an innovative investment portfolio consisting of more than 25 companies, including Arcus Biosciences, Cullinan Pearl, Dren Bio, Orna Therapeutics and Werewolf Therapeutics.

The increase in the investment pool demonstrates Taiho Ventures’ strong commitment to its continuous support of innovative biotech start-ups pursuing cutting-edge drug discovery activities based on state-of-the-art science. Taiho Pharmaceutical also aims to accelerate its open innovation through these investment efforts.

Taiho Pharmaceutical and Taiho Ventures are committed to sustainable delivery of new technologies and treatment options to patients in need.

About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and allergy/immunology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en/

About Taiho Ventures, LLC
Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology. Taiho Ventures is looking at early-stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review the wide variety of modalities for both biologics and small molecules. The company will also consider the option type of investments and spin-outs, in addition to the pure equity investments. For more information about Taiho Ventures, please visit https://www.taihoventures.com/

Taiho Pharmaceutical Contact:
Junko Onishi
Taiho Pharmaceutical Co., Ltd.
+81-3293-2878
[email protected]

Taiho Ventures Contact:
Yuichi Fukushima
Taiho Ventures, LLC
[email protected]

SOURCE Taiho Pharmaceutical Co., Ltd.

IRVING, Texas, Jan. 8, 2024 — Today, Care Continuity, a leader in data-driven patient navigation serving some of the country’s largest health systems, payers, and ACOs, announced the close of $10 million in Series A-3 funding co-led by Empactful Capital & Viewside Capital Partners with participation from Flat Creek Capital and Loop 289 Limited Partners.

The funding will enable Care Continuity to further its mission of helping health systems, payers and ACOs employ an efficient patient and member-centered care journey, as well as make strategic investments in growth, product development, and further enablement of AI to enhance Care Continuity’s already strong patient navigation offerings.

“As health systems grow in complexity, the need for compassionate, patient-centered services that help patients along their care journey has increased exponentially,” said Brad Prugh, CEO of Care Continuity. “Health systems have invested heavily in building comprehensive healthcare networks and want to see their patients fully utilize these networks. That’s where Care Continuity thrives.”

“This funding will allow us to enhance our navigation platform in meaningful ways for both providers and patients. This includes employing AI to increase our ability to expand our reach and improve the efficiency in which we connect with more patients,” said Prugh.

In addition to assisting health systems in reducing patient leakage by providing patient-centered navigation, Care Continuity’s advanced analytics, purpose-built digital tools, and one-to-one concierge interactions also provide payers, ACOs, and other risk-bearing entities in healthcare with a quality medium to engage members and navigate them to network care.

“Care Continuity’s patient navigation solutions address many of the problems patients face in our fragmented healthcare system,” said Sal DeTrane, Managing Director at Empactful Capital. “By efficiently and compassionately navigating patients along their care journey, Care Continuity helps health systems, payers and ACOs serve their patients and members while improving the integrity of their care networks.”

The announcement comes on the heels of impressive growth for the company, including a 60% Revenue CAGR, a 155% increase in navigated patients, and expansion of their product offering. The company has continued to build out its management team, including key hires in sales and marketing, technology, data science, and advisory services. 

About Care Continuity

Founded in 2014, Care Continuity provides expert patient navigation solutions that are designed to bridge gaps in healthcare, providing seamless transitions between care settings, reducing network leakage, and promoting optimal health outcomes and patient satisfaction. Through a combination of advanced software, AI and a dedicated team of care concierges, we help guide patients through their care journey while maintaining the integrity of the health system network. This translates to greater patient satisfaction, better health outcomes, and increased margins for our clients.  To learn more, visit www.carecontinuity.com or follow us on LinkedIn.

About Empactful Capital

Empactful Capital, founded in 2016 by experienced healthcare professionals and investors, is a venture capital firm specializing in early and growth-stage opportunities within the healthcare sector. Our primary focus is on whole-person value-based models and behavioral health. Using targeted funds and industry expertise, we aim to quickly scale innovative companies. Through our pre-investment working engagement model, we thoroughly assess areas of strength and development to ensure alignment and drive success for the companies we invest in. In 2021, Empactful Capital served as the lead investor for Care Continuity from its first fund and co-led the most recent investment into The Company from its second fund.

Media Contact: Tim Anderson, [email protected]

SOURCE Care Continuity

CHICAGO, Jan. 7, 2024 — WellBe Senior Medical, an in-home value-based care provider to the Medicare Advantage population, announced an investment from CVS Health Ventures, the corporate venture capital arm of CVS Health. This strategic partnership and investment will help to accelerate WellBe’s national expansion. Today, WellBe operates in seven states, has over 107,000 Medicare Advantage members and over $2 billion in premium under management, and is the fastest-growing independent provider of value-based care in the home for Medicare Advantage.

The company’s rapid growth underscores the critical need for better solutions and investment in senior healthcare. “CVS Health Ventures is committed to helping provide seamless access to quality health care, especially for vulnerable populations like seniors,” says Vijay Patel, Managing Partner of CVS Health Ventures. “WellBe’s innovative approach to in-home medical care aligns with our vision of redefining the way health care is delivered in a multi-payor, patient-centric manner. Our collaboration with WellBe will support their mission to empower seniors to live healthier, happier lives in their homes.”

WellBe’s prescribing providers bring specialized geriatric care into the patient’s home. Many of the services available from a typical physician clinic are now delivered to the home, proactively managing care for the sickest and most complex Medicare Advantage patients. WellBe partners with Medicare Advantage health plans via global capitated risk arrangements to manage the ten to fifteen percent of members with very high and rising medical loss ratios. This allows WellBe to guarantee savings up front to the health plan and take on the risk of managing this costly population. By delivering proactive medical care at home, available to patients 24/7/365, WellBe’s best-in-class model helps avoid unnecessary hospitalizations, reducing total medical cost while improving overall patient satisfaction. Additionally, WellBe improves HEDIS ­­measures leading to an increase in Star Ratings from a low of 2.5 to a high of 4.5.

WellBe was cofounded by Chicago Pacific Founders (CPF) and provided the capital to grow WellBe to this point. CPF invests in founder-led healthcare services companies and helps drive healthcare services innovation forward. “WellBe has proven its ability to significantly improve the quality and health outcomes for the sickest and most frail in our communities,” said Mary Tolan, Founder and Managing Partner of CPF. “We are passionate about WellBe’s commitment to providing the level of care we want for our family members and loved ones. The patient outcomes speak profoundly of the company.”

“All of us have had an elderly friend or family member whose health increased in complexity with age, limiting every aspect of their life,” said Dr. Jeffrey Kang, Founder and CEO of WellBe Senior Medical. “This makes traditional office-based care inconvenient, unresponsive, and often unavailable when it’s needed. Instead of trying to bring these frail patients to the care, the solution is to brin­­g the care to the patient, in the comfort of their own home. We’ve found that WellBe can provide more than 90 percent of what occurs in a primary care doctor’s office conveniently at home. Access to WellBe’s in-home geriatric care should be available to everyone, which is why we’re passionate about partnering with payors nationwide, removing yet another barrier to care for patients. This collaboration with CVS Health Ventures fuels our mission to share our proven care model with more payors, more communities, and more patients.”

About WellBe Senior Medical
WellBe Senior Medical works with health plans to provide home-based medical care (HBMC) to patients who are facing multiple complex health challenges. WellBe’s providers are committed to providing personalized CompleteCare™ wherever our patients call home. Our care team works together with patients, their caregivers, and physicians to nurture all aspects of health. For more information, or to see if you or a loved one is eligible to receive care from WellBe Senior Medical please visit wellbe.com or call 1-855-493-5523.

About CVS Health Ventures
CVS Health Ventures is a dedicated corporate venture capital fund that works with high-potential, early-stage and growth-stage companies focused on making health care more accessible, affordable, and simpler. The company focuses on investments that transform care delivery and focus on whole person care, consumer-centric health, and disruptive technology enablement. CVS Health Ventures’ goal is to enable promising entrepreneurs to scale more quickly and effectively through access to their unmatched enterprise capabilities and consumer touchpoints, while offering expertise and insights from their company’s unique perspective. For more information, visit cvshealth.com/health-care-redefined/ventures.html.

About Chicago Pacific Founders
Based in Chicago and San Francisco, Chicago Pacific Founders (“CPF”) is a leading strategic private equity firm focused on investing in growth companies within value-based care, healthcare services, AI and tech enabled services, and caring for aging populations. CPF believes that the most significant societal impact and investment returns from healthcare for the next decade will be generated by investment in delivery model innovation. CPF’s leadership team is made up of former healthcare founders, senior executives, and investment professionals with a passion and track record of building healthcare businesses. Additionally, CPF has a vertically integrated Senior Housing strategy and a complementary medical office investment strategy that leverages CPF’s extensive healthcare industry relationships. For more information, please visit www.cpfounders.com.

CONTACT: Brian Reuhl
[email protected]

SOURCE WellBe Senior Medical

SHANGHAI, China, Jan. 5, 2024 — On January 5, 2024, USHOPAL GROUP (hereinafter referred to as USHOPAL), a leading luxury beauty and retail group in China, announced its lead investment in the new multi-million dollar round of financing of high-end Chinese fragrance brand, DOCUMENTS, readying for the global stage. This investment represents USHOPAL’s first equity investment in a Chinese domestic brand. This move further confirms the significant position of Chinese brands in USHOPAL’s business layout and underscores the strategic deployment of Chinese beauty brands in USHOPAL’s future investments. Investing in DOCUMENTS indicates USHOPAL’s commitment to providing DOCUMENTS with more international exposure and dialogue opportunities with global brand leaders.

As the founder and CEO of USHOPAL, Lu Guo, expressed, ‘USHOPAL only collaborates with the world’s top-tier brand teams. Over the past years, the company has actively sought outstanding Chinese high-end beauty brands. The investment in DOCUMENTS marks USHOPAL’s first venture into the domestic market, signifying our belief that China has produced brands capable of stepping onto the global stage.’ The management team at USHOPAL also stated, ‘When evaluating brands and founding teams, we consider factors such as the maturity of brand positioning, effectiveness of emotional communication, consistency and stability in product development, and most importantly, the unique artistic expression and brand personality. DOCUMENTS is one of the very few Chinese brands that can compete with global high-end brands in these aspects.

Zhaoran Meng, the founder of DOCUMENTS, stated, “DOCUMENTS has always aimed to awaken sensory resonance among urban residents and communicate the contemporary taste of Chinese people’s lifestyles through novel and profound olfactory experiences. Accepting investment from USHOPAL this time, we hope to leverage its professional expertise and leading position to strengthen our brand’s creative advantages in aesthetics. Additionally, we aim to gain more benefits in global channels, business operations, and supply chain management, working towards enhancing competitiveness and evolving into a more visionary international brand.

About USHOPAL

USHOPAL Group was established in 2017, and within a few short years since its inception, it has successfully managed and operated several internationally renowned beauty brands in China, including Chantecaille, 111SKIN, SUQQU, Juliette Has A Gun, and others. The group has also made multiple investments in globally influential high-end beauty brands. In 2022 and 2023, USHOPAL completed the acquisition of the top British skincare brand ARgENTUM, and the French luxury fragrance brand Juliette Has A Gun. Additionally, it invested in several well-known international brands, including the leading Japanese DTC men’s brand BULK HOMME. These strategic moves have enabled USHOPAL to build a diverse portfolio of high-end beauty brands, covering skincare, cosmetics, perfumes, maternity and baby care, and men’s grooming.

About DOCUMENTS

DOCUMENTS is the first high-end fragrance brand in China to receive venture capital from L’Oréal. pioneers the “Bold-Zen” style, and cooperates with world-class fragrance companies to launch series of fragrances with perfume ratios ranging from 15% to 40%, as well as several diverse fragrance product series, with the mission of ‘creating unforgettable profound fragrances that help people be smelled and remembered’, combining traditional Oriental culture with contemporary design aesthetics. DOCUMENTS has now already opened directly operated stores in prime locations of the top cities nationwide in China, showcasing the new strength of contemporary Chinese brands to the world by unique and profound sensory experiences.

For media enquiries, please contact: 
Investor Relations
pr@USHOPAL.com 

SOURCE USHOPAL

Affinity is a Compliance Training Platform Built for Regulated Industries.

GREENWICH, Conn., Jan. 5, 2024 — O’Shaughnessy Ventures LLC (“OSV”), a family office that invests in ambitious seed and pre-seed startups, announced today that it has invested in Affinity Learning Inc. (“Affinity”).  Founded in 2023 by Faraz Rana and Peter Greczner, Affinity is a modern compliance training solution built for regulated industries. It aims to revolutionize the compliance training industry by enabling organizations like financial technology companies and banks to deliver customized and real-time embedded guidance into existing workflows.

OSV’s founder, Jim O’Shaughnessy, commented; “Industries that were once unaffected by compliance regulations are now facing greater scrutiny. Affinity provides leaders with the tools to train and educate their workforce on compliance-related issues, providing companies with a competitive advantage and acting as a protective measure against potential adverse events.”  “Traditional compliance training as it’s been done for decades simply does not work,” said Affinity cofounder and CEO Rana, who, along with co-founder Greczner, helped build and scale financial technology startup Bread to a $500 million exit in 2020; “Affinity is here to change that for good. We’ve all seen it time and time again: Regulated companies that are able to build a culture of compliance just scale better in the long run. We’re excited to welcome OSV, a company that aligns with our vision.”

About O’Shaughnessy Ventures

OSV is a family office that invests in ambitious seed and pre-seed startups. Founded by Jim O’Shaughnessy, a pioneer in quantitative investing, founder of O’Shaughnessy Asset Management, and author of four books on investing, OSV aims to provide financial support and to partner in growing the next life-changing ideas. For more information, visit https://www.osv.llc/

Media Contact:
Ena Gong
O’Shaughnessy Ventures LLC
(917) 355-7420
370826@email4pr.com

SOURCE O’Shaughnessy Ventures LLC

JACKSONVILLE, Fla., Jan. 5, 2024 — When seasoned entrepreneur and longtime life science executive Tony Munoz launched alteredFLIP in 2019, he set out to change the way business is conducted when it comes to fix-&-flip construction.  While most fix-&-flip construction companies are purely concerned with the bottom line, Tony and his alteredFLIP team take an entirely different approach, focusing on all the people involved in the transaction, including the future homeowner.

“We specialize in dealing with distressed situations, not just distressed real estate,” says Tony Munoz, Founder and CEO of alteredFLIP.  “Our goal is to add value in the asset through rehab and construction so that the end consumer, the new first-time homeowner, has an opportunity to own a home where innovation and value are prioritized. We want to also make sure that the future homeowner purchases the home with built in equity.”

alteredFLIP, which operates all over Florida, but is based out of Jacksonville, Tallahassee, and Miami, offers sellers all-cash offers for their homes with fast settlement terms, often closing in just two or three weeks. alteredFLIP takes on complex situations such as homes with back taxes, mechanical liens or distressed properties that have become an eye sore in the neighborhood. Buying at a discount allows the company to pass on the equity to the future homeowner post construction. The company is known in each of their markets as a quality construction company that prioritizes craftmanship, design, and a “customer first” attitude.

For more information on the Inward/Outward Project, visit their website at https://alteredflip.com.  

About alteredFLIP:

Founded in 2019 by veteran entrepreneur Tony Munoz, alteredFLIP is a construction company specializing in distressed real estate.  Their customer-first approach sets them apart from the competition by placing the needs and requirements of their sellers and future home owners above everything else.

For more information or to get a no obligation, all-cash offer on a property, visit their website at https://alteredflip.com or http://tonybuyshouses.com.

Media Contact:

Tony Munoz
Chief Rehab Officer
alteredFLIP
786.414.0347
[email protected]

SOURCE alteredFLIP

• New financing, led by Cathay Innovation, will be used to expand capabilities and adoption of Nabla Copilot, the leading ambient AI assistant designed to alleviate the administrative burden placed on providers, and reduce clinician burnout.
• Launched in March 2023, Nabla Copilot has experienced rapid growth with +20,000 providers who have already adopted the solution for its accessibility, accuracy, and speed, and have helped build Copilot to better serve the provider community’s needs.

BOSTON, Jan. 5, 2024 — Nabla, the leading ambient AI assistant for practitioners, today announced the initial close of a $24M Series B funding round led by Cathay Innovation, with participation from ZEBOX Ventures. This close brings Nabla’s total funding to over $43M. This investment enables Nabla to boost expansion across U.S. healthcare systems and continue transforming the way providers deliver care with its ambient AI assistant.

Clinicians have deemed managing the electronic health record (EHR) the biggest stressor in patient care. Clinical documentation is a time-intensive task that adds six hours per week of EHR work for practitioners outside of standard time spent with patients. With its AI-powered note-generation capabilities, medical coding recognition, and smooth EHR integrations, Nabla Copilot is saving clinicians valuable time so they can focus on caring for their patients. Providers claim the notes are remarkable for their precision, with only 5% requiring adjustments.

In addition to nationwide expansion, the Series B funding will allow the company to fuel its ambition to build the most intuitive and reliable ambient AI that can support clinicians across the clinical spectrum up until medical decision support. The investment will also contribute to Nabla’s commitment to improving health equity with the launch of additional language options for Nabla Copilot.

“This fundraise allows us to continue delivering on our vision to build the premier ambient AI assistant that will allow clinicians to experience the joy of practicing again,” said Alex Lebrun, co-founder and CEO, Nabla. “Clinical documentation is only the beginning for Nabla. Health systems are looking to leverage the AI opportunity to support their healthcare teams  in many different aspects; we are getting ready to be there every step of the way.”

“Nabla’s exceptional team understands clinicians’ pain points and has the deep, technical expertise needed to bring cutting-edge AI and LLM technologies to the healthcare industry and best support practitioners shifting back to a patient-centric approach,” said Jacky Abitbol, Managing Partner, Cathay Innovation. “The company has demonstrated impressive early traction in both Europe and the US, and we look forward to putting our global network and resources to work to help Nabla expand further and solidify their position at the heart of new AI medical applications.”

Less than ten months since its official launch, Nabla reports three million consultations are conducted through Nabla Copilot annually, and more than 20,000 providers have adopted the ambient AI assistant, providing enthusiastic reviews that reflect its impact.

• “Prior to using Nabla, It was harder to complete the office notes same because of the time constraint. Since, I started using Nabla, I am able to complete my notes the same day as the office visit and many times I am able complete the notes after seeing every patient. This is a stress reliever for me. Now, it is harder to imagine life without Nabla.” – Dr. Raghu K
• “With Nabla, I am finally getting my weekends back. What took 8-10 hours now takes maybe 3-4 hours. Better yet, because I no longer need to be a scribe, I get to actually be a psychologist and focus on my patient! After only a couple of months, I can’t imagine my practice without Nabla.” – M. Tursich, PhD, Psychologist

Nabla also prides itself on being scalable, having the capacity to cater to the unique needs of both small practices and large health systems with 10,000+ clinicians. To deliver its solution to a broader user base, Nabla has partnered with EHR platforms that are increasingly looking to embed AI solutions like Nabla Copilot, which provide smooth integrations and streamline workflows while prioritizing privacy, accuracy, and speed.

Founded in 2018, Nabla has proprietary Large Language Models (LLM) and Speech-to-Text (STT) technologies built by former Facebook AI Research engineers. Nabla’s advisors include AI and medical experts, including the godfather of AI, Yann LeCun; Dr. Megan Mahoney, Professor and Chair at UCSF Department of Family and Community Medicine; Dr. Haipeng (Mark) Zhang, Associate Program Director of the Clinical Informatics and Innovation Fellowship at Brigham and Women’s Hospital; and Dr. Andrew Lundquist, Chief Medical Officer of the Mankato Clinic.

Available on mobile, desktop, and API, Nabla continually improves its user experience by applying feedback from its engaged clinician community. The company does not store data, complying with the highest confidentiality and privacy regulations. 

About Nabla
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again. AI-powered Nabla Copilot generates clinical notes in seconds from any encounter across all specialties, reducing practitioners’ stress and improving patient care. Nabla Copilot’s capabilities also include AI-enabled medical coding identification, and smooth EHR integrations.

The company’s advisors include Yann LeCun, VP & Chief AI Scientist at Meta, also known as one of the founding fathers of artificial intelligence, Megan Mahoney, chair of the UCSF Department of Family and Community Medicine, Dr. Haipeng (Mark) Zhang, Associate Program Director of the Clinical Informatics and Innovation Fellowship at Brigham and Women’s Hospital; and Dr. Andrew Lundquist, Chief Medical Officer of the Mankato Clinic.
Investors include global venture capital firm Cathay Innovation, as well as seasoned entrepreneurs such as CMA CGM Group Chairman and CEO Rodolphe Saadé, tech entrepreneur Xavier Niel, Tony Fadell, co-creator of the iPod and iPhone, as well as Rachel Delacour, CEO & Co-founder at Sweep, among others. Since its launch in 2018, Nabla has raised a total of $43M.

For more information, please visit: www.nabla.com.

Media Contact 
[email protected]

SOURCE Nabla

Hatz AI Launching the First Platform Built for MSPs to Deliver AI to their Customers

NEW YORK, Jan. 4, 2024 — Hatz AI, Co-Founded by Jimmy Hatzell and serial entrepreneur Aidan Kehoe, publicly launches today, announcing a $2.5 million seed funding round led by Vestigo Ventures. Hatz AI enables MSPs to build an AI-as-a-Service business with AI applications, AI agents, vector storage, and custom Large Language Models (LLMs) powered by an LLM Ops engine and managed through a multi-tenant platform.

The company is set to make their products generally available in March, aiming to empower Managed Service Providers (MSPs) worldwide to build AI-as-a-Service Businesses.

“MSPs will play a key role in the global transition to AI,” stated Jimmy Hatzell, CEO of Hatz AI. “I think every MSP will soon manage and own their own LLMs, and provide similar services for their customers. We are building a system of record for MSPs to manage that transition and a system of engagement to operationalize the technology.”

“The platform allows PCH Technologies to provide AI-as-a-Service in an easy to use format that is secure and customizable that will create a competitive advantage to our clients by accelerating the adoption of AI in each individual business,” said Tim Guim, CEO of PCH Technologies and Hatz AI MSP Launch Partner.

The funding round, led by Vestigo Ventures, features a prestigious group of investors including Alex Weiss from ClearSky, Matt Higgins from Shark Tank and RSE Ventures, Jim Brown from Long Ridge, Jon McNeill, founder of DVx Ventures and former president of Tesla and former COO of Lyft, Iqram Magdon-Ismail, musician and Co-founder of Venmo, and Aidan Kehoe, Nadia Partners.

“MSPs are entrepreneurial, customer-obsessed, and essential to the adoption of innovative technologies by the information economy. These are the kind of folks we love working with at Vestigo and we are thrilled to partner with Jimmy and Aidan to build the first MSP-native customer AI platform.” said Frazer Anderson, Principal at Vestigo Ventures. “These entrepreneurs were made for this business and we are proud to support them on what we’re sure will be a joyous journey.”

Hatz AI is launching its first generally available products in March of 2024. The first release will include both an AI Application Builder and Organizationally Managed AI Assistants. Later this year Hatz AI will make their AI Phone Customer Service Agents generally available, as well as the ability to train and manage vector databases and custom LLMs inside the multi-tenant platform.

About Hatz AI: Hatz AI enables MSPs build an AI-as-a-Service business with AI applications, AI agents, vector storage, and custom LLMs powered by an LLM Ops engine and managed through a multi-tenant platform. Hatz AI is currently signing up new MSP partners through a waitlist available on their website, https://hatz.ai.

SOURCE Hatz AI Inc